Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
60 hedge funds and large institutions have $297M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
39% more capital invested
Capital invested by funds: $214M → $297M (+$82.8M)
2% more funds holding
Funds holding: 59 → 60 (+1)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.27M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$4.3M |
| 3 |
VMI
VHCP Management II
New York
|
+$3.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.26M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.79M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.48M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$1.33M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.24M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $31K | -$17.7K | -926 | -39% |
|
52
Legal & General Group
London,
United Kingdom
| $27K | – | – | – |
|
|
AIP
53
Ameritas Investment Partners
Lincoln,
Nebraska
| $15K | +$13.7K | +715 | New |
|
|
FPFS
54
First Personal Financial Services
Charlotte,
North Carolina
| $13K | – | – | – |
|
|
CCA
55
Catalyst Capital Advisors
Huntington,
New York
| $10K | +$9.18K | +480 | New |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | -$5.22K | -273 | -55% |
|
|
IUHSA
57
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| $3K | +$3.06K | +160 | New |
|
58
Citigroup
New York
| $2K | -$156K | -8,158 | -99% |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| $2K | +$612 | +32 | +47% |
|
|
MAM
60
Meeder Asset Management
Dublin,
Ohio
| $2K | +$1.51K | +79 | New |
|
61
BNP Paribas Financial Markets
Paris,
France
| $1.49K | +$1.34K | +70 | New |
|
|
LCM
62
Laurion Capital Management
New York
| – | -$608K | -40,000 | Closed |
|
63
Norges Bank
Oslo,
Norway
| – | -$304K | -20,000 | Closed |
|
RARX Hedge Fund Activity: Q1 2017 in Review
60 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q1 2017, worth a combined $297M — up 39% from $214M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RARX positions and 4 closed out — a net gain of 8 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $6.27M. The largest seller was Deerfield Management, cutting an estimated $2.79M.
- 60 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q1 2017, up from 59 in Q4 2016.
- Funds reported $297M of Ra Pharmaceuticals, Inc. Common Stock stock for Q1 2017, up 39% quarter-over-quarter.
- 12 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q1 2017 and 4 closed out, a net change of +8 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $6.27M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q1 2017 was Deerfield Management, an estimated $2.79M sold.
Based on aggregated 13F filings for Q1 2017.